Background {#Sec1}
==========

Malaria in pregnancy is a major public health problem in Uganda \[[@CR1]\], responsible for anaemia among pregnant women and low birth weight in infants \[[@CR2]\]. The current policy for treating malaria in pregnancy in the first trimester is to give quinine 10 m/kg; and during the second and third trimester, artemisinin-based combination therapy (ACT) is recommended. For malaria prevention in Uganda, the policy recommends at least three doses of sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment (IPTp), and use of insecticide-treated bed nets (ITNs) \[[@CR3]\]. Adherence to the guidelines (not to give ACT or any anti-malarial monotherapies during the first trimester) would ensure effective treatment of malaria and patient safety.

Although utilization of health-facility based interventions like antenatal care (ANC) and delivery care is generally poor \[[@CR4]\], SP-IPTp has one of the lowest implementation rates compared to other interventions in pregnancy and childhood. Recent data shows that low utilization of essential health services leads to missed opportunity. For example, 47.6 % pregnant women attend the required four antenatal care visits; 26.7 % receive the two doses of SP-IPTp while 55.5 % get at least two doses of tetanus toxic vaccination \[[@CR4]\]. Previous studies have assessed factors associated with low utilization of health-based interventions, including maternity services, and have documented socio-cultural factors, economic, constraints, negative perceptions, poor quality of care and long distances to health units \[[@CR5]--[@CR14]\].

Several studies have implemented private-sector interventions aimed at increasing access to malaria prevention services in Uganda. One study implemented at a community level, assessed whether drug shops, traditional birth attendants, community health workers and peer adolescent mobilizers would increases access to essential maternity services. The study demonstrated increased access to two doses of SP with an impact on pregnancy outcomes \[[@CR15], [@CR16]\]. It was further shown that the distribution of SP at a community level did not negatively affect access to essential health services at health facilities \[[@CR2]\]. Another study assessed the feasibility of private midwives in prevention of mother-to-child transmission of human immune deficiency virus (HIV) \[[@CR17]\]. The study showed that private midwives were already providing essential maternity services; and they were trusted by their communities. Despite this scenario, access to HIV and malaria preventive services was low among the poor, the young and the less educated women. Following this study, it was recommended that private midwives be given refresher courses, to improve the quality of services \[[@CR17]\].

It has also been shown that many patients (including pregnant women) with febrile illnesses receive anti-malarial drugs and only 34 % of malaria patients received an appropriate ACT regimen. This practice is due to the continued practice of presumptive treatment, inadequate training on malaria management and lack of knowledge that artemether-lumefantrine (Coartem^®^) was the recommended first-line treatment for malaria in Uganda \[[@CR18]\].

Based on the above evidence, and the need to scale up services to achieve universal coverage, Uganda formulated a public--private partnership policy and is currently discussing modalities for its implementation \[[@CR1]\]. Studies to guide this process are required, including exploring the feasibility of involving the private health sector in prevention and control of malaria in pregnancy. The main objective of the study was to assess quality of care in the private sector for patients seeking care in this outlet \[[@CR19]\]. Specifically the sub-study assessed existing malaria prevention and treatment practices in the private sector in order to design effective interventions to improve access and quality of care for pregnant women seeking treatment in this sector.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

The study design is reported elsewhere \[[@CR19]\], but briefly the study was undertaken in Mukono district, bordering Lake Victoria in Central Uganda. The district area is endemic for malaria, with high disease prevalence around May--June and November--December. The district population is estimated at 565,700 with an annual growth rate of 2.3 % \[[@CR16]\]. Most people, 88 %, live in the rural areas; access to ANC (at least one visit) is high, 94.1 %; however, only 26.7 % of pregnant women receive the two or more doses of SP as recommended by policy \[[@CR4]\].

A survey was conducted from August to October 2014. A list of all parishes from which sampling was done was obtained from Uganda Bureau of Statistics, Kampala. The criteria for selecting study parishes were: (i) contained more than 200 households to ensure a sufficient number of patients visiting the facilities; (ii) contained a health centre II, the lowest public health facility where early treatment and referral is sought; and (iii) contained at least one registered drug shop, pharmacy or private clinic. In total, 57 parishes with 242 private facilities were selected to implement the study A structured questionnaire was used to collect data targeting one provider who was found on duty in each selected private health facility.

Both the facility and its health workers were assessed using a semi-structured questionnaire. One staff in each private facility (drug shops, private clinics and pharmacies) and higher level (Health Centre II, III, IV and hospitals) that consented to the study was interviewed. In higher referral facilities the study targeted in-charges or deputies in the higher level facilities and whoever was present on the day of the interview.

The study outcome was the proportion of private health facilities who prescribe treatment of fever among pregnant women as recommended in the guidelines (quinine, 10 m/kg in the first trimester; and ACT in the second and third trimester \[[@CR3]\]).

Data collection methods {#Sec4}
-----------------------

Data was captured on the following variables: provider characteristics, previous training received, type of drugs stocked, knowledge on treatment and prevention of malaria in pregnancy. The interviews were conducted by experienced research assistants, who underwent refresher training for 5 days on research techniques, and study procedures; and participated in the pretesting and revision of the questionnaire tools before actual field work. Since all private providers had a working knowledge of English, the questionnaires were administered in English language. All aspects of data collection were supervised.

Sample size calculation {#Sec5}
-----------------------

Sample size calculation was based on the proportion of private health facilities prescribing treatment of fever among pregnant women as recommended in the guidelines (quinine, 10 m/kg in the first trimester; and ACT in the second and third trimester) estimated at 25 %. In order to estimate the proportion with a ±7 % absolute precision, at a power of 80 and 5 % level of significance (two-sided), a minimum of 232 private health facilities were required.

Statistical methods {#Sec6}
-------------------

Data was entered using Microsoft Access 2007 (Microsoft Inc., Redmond, Washington) and analysed using STATA version 11.0 (STATA Corporation, College Station, Texas). Proportions on key variables were calculated using univariate analyses; factors associated with treatment of fever among pregnant women were assessed using bivariate analyses. Variables with a *p* value \<0.05 were included in a logistic regression model that assessed factors associated with correct treatment of fever among pregnant women. The robustness of the regression model was tested using a Hosmer--Lemeshow goodness of fit Chi Square test and considered significant at a *P* \>0.05.

Ethics {#Sec7}
------

Ethical approval for the research was granted from review boards at the Uganda National Council of Science and Technology (Ref: ss 3529). Written informed consent was sought prior to the interviews. The collected data could only be accessed by the researchers to ensure confidentiality.

Results {#Sec8}
=======

Characteristics of private health facilities {#Sec9}
--------------------------------------------

A total of 241 private health care facilities were surveyed; 70.5 % were drug shops; 24.5 % were private clinics and 5.0 % were pharmacies. The majority, \>73 % were registered; and most (\>75 %) were registered with the National Drug Authority; others were registered at the district level.

All the facilities sold anti-malarial drugs (Table [1](#Tab1){ref-type="table"}). Almost all were stocked with artemisinin-based combinations (artemether-lumefantrine), the first-line anti-malarial drug and the majority, 82 % were stocked with quinine (the second-line anti-malarial drug). The majority, over 78 % also stocked SP. However, a sizeable proportion also stocked other anti-malarial monotherapies which are no longer recommended: such as chloroquine, 12.4 % at drug shops and amodiaquine (Camoquine^®^, 10.2 % at private clinics). Most of the facilities were busiest in the morning and evenings. The majority of private clinics (84.8 %) had patient registers; but only a few of the drug shops had a patient register, 21.2 %. Few of the private clinics, 25 % or drug shops, 16 % had stock cards. RDTs were available for malaria diagnosis in more than 75 % of pharmacies and private clinics, and in 43.8 % of registered drug shops. In contrast, only 44 % of private clinics, 42 % of pharmacies and 18 % of drug shops were equipped with the current national malaria treatment guidelines.Table 1Characteristics of private health care facilitiesCharacteristicsRegistered drug shops N = 170Private clinics N = 59Pharmacy N = 12Type of facility170 (70.5 %)59 (24.5)12 (5.0 %)Facility location130 (76.5 %)53 (89.8 %)11 (91.7 %)Urban rural40 (23.5 %)6 (10.2 %)1 (8.3 %)Facilities registered125 (73.5 %)54 (91.5 %)12 (100 %)Where facilities are registered District (receipt seen)29 (23.6 %)8 (14.9 %)0 (0.0 %) NDA (license seen)93 (75.6 %)45 (83.3 %)12 (100 %) No response1 (0.9 %)1 (1.9 %)0 (0.0 %)Busiest time at this facility Morning (up to 12 pm)46 (27.1 %)25 (42.4 %)9 (75.0 %) Afternoon (12--5 pm)10 (5.9 %)7 (11.9 %)0 (0.0 %) Evening (5--7 pm)19 (46.5 %)17 (28.8)1 (8.3 %) Night (7--12 am)20 (11.8 %)5 (8.5 %)2 (16.7 %) Facilities with a patient register36 (21.2 %)50 (84.8 %)7 (58.3 %) Facilities with stock control cards27 (15.9)15 (25.4)7 (58.3) Facilities with malaria treatment guidelines30 (17.9)26 (44.1)5 (41.7) Facilities with a thermometer160 (94.1)58 (98.3)11 (91.7) Facilities with an RDT for malaria diagnosis74 (43.8)54 (89.8)9 (75.0) Facilities selling anti-malarial drugs170 (100)59 (100)7 (100) Chloroquine21 (12.4)4 (6.8)5 (41.7) Fansidar (SP)134 (78.8)52 (88.1)12 (100) Camoquin11 (6.5)6 (10.2)1 (8.3) Quinine141 (82.9)53 (89.8)11 (91.7) ACT166 (97.7)57 (96.6)12 (100)

Provider characteristics {#Sec10}
------------------------

Providers were predominantly female, especially in drug shops, 87.7 % compared to 56.0 % in private clinics and 58.3 % in pharmacies (Table [2](#Tab2){ref-type="table"}). Similarly, the majority of providers at drug shops 52.9 % had not progressed beyond secondary education while at private clinics and pharmacies, the majority had attained tertiary education. Most providers at drug shops were of lower professional cadre (nursing assistants, nursing aides, enrolled nurses/midwives); while at private clinics providers were of a higher professional cadre (registered nurses/midwives and clinical officers).Table 2Providers characteristics at private health care facilitiesProviders characteristicsRegistered drug shops N = 170Private clinics N = 59Pharmacy N = 12Sex Male21 (12.3)26 (44.0)5 (41.7) Female149 (87.7)33 (56.0)7 (58.3)Education Secondary90 (52.9)12 (20.3)0 (0.0) Tertiary80 (47.1)43 (72.9 %)10 (83.3) University0 (0.0)4 (6.8)2 (16.7 %)Level of professional training Nursing aide11 (6.5)0 (0.0)11 (4.6) Nursing assistant82 (48.2)6 (10.2)2 (16.7) Enrolled nurse/midwife52 (30.6)6 (10.2)2 (16.7) Registered nurse/midwife6 (3.5)7 (11.9)0 (0.0) Clinical officer4 (2.4)14 (23.7)2 (16.7) Doctor0 (0.0)3 (5.1)0 (0.0)

Treatment and prevention of febrile illnesses in pregnancy {#Sec11}
----------------------------------------------------------

Private providers were asked what treatment they give to pregnant women who present with fever to their facilities. Treatment of pregnant women with fever according to the guidelines was 40.7 % at private clinics, 28.2 % at drug shops and 16.7 % at pharmacies. A big proportion, 45.9 % of drug shops prescribed SP as first-line treatment for malaria to pregnant women; while 2.9 % prescribed ACT. The majority of providers (\>75 %) at all private facilities prescribed SP for intermittent preventive treatment (IPTp) but artemisinin-based combination therapy (ACT) was also prescribed: 8.3, 6.9 and 8.3 % respectively at drug shops, private clinics and pharmacies for prevention of malaria in pregnancy.

Knowledge on pregnant women being vulnerable to malaria was low, 11.2 % at drug shops, 6.8 % at private clinics and none at pharmacies. Most providers, \>89 % recommended ITNs to pregnant women for malaria prevention (Table [3](#Tab3){ref-type="table"}). The following factors were associated with correct treatment given to pregnant women with fever: the type of facility (drug shop), *P* = 0.04; knowledge of people vulnerable to malaria, *P* = 0.02; and availability of a malaria treatment guideline, *P* = 0.03 (Table [3](#Tab3){ref-type="table"}).Table 3Level of knowledge, treatment and prevention of malaria in pregnancy at private health facilitiesKnowledge, treatment and prevention of malaria in pregnancyRegistered drug shops N = 170Private clinics N = 59Pharmacy N = 12Knowledge about of people at risk of malaria All people24 (14.1)10 (17.0)9 (41.7) Children (0--5)58 (43.1)30 (50.9)5 (41.7) Children (6--15)61 (35.9)10 (17.0)1 (8.3) Adults8 (4.7)4 (6.8)0 (0.0) Pregnant women19 (11.2)4 (6.8)0 (0.0)Treatment given to pregnant women with fever according to the guideline First trimester give quinine and second trimester give (ACT) as recommended by the guideline48 (28.2)24 (40.7)2 (16.7)Drugs given to pregnant women who present with fever ACT5 (2.9)4 (6.8)1 (8.3) SP78 (45.9)11 (18.6)3 (25.0) Quinine12 (7.1)7 (11.9)2 (16.7) Paracetamol12 (7.1)4 (6.8)2 (16.7) Other (amoxicillin, folic acid, iron)15 (8.8)9 (15.3)2 (16.7)Anti-malarial drug given to for malaria prevention Quinine5 (3.0)0 (0.0)1 (8.3) ACT14 (8.3)4 (6.9)1 (8.3) SP128 (76.2)52 (89.2)9 (75.0) Other (amoxicillin, chloroquine, vitamin B-complex)21 (12.5)2 (3.5)1 (8.3)Malaria prevention interventions providers recommend to pregnant women Insecticide treated nets (ITNs)152 (91.0)52 (89.7)12 (100) In-door residual spray (IRS)2 (2.4)2 (3.5)0 (0.0) Advice on good nutrition3 (1.8)2 (3.5)0 (0.0) Close windows early3 (1.8)1 (1.7)0 (0.0)Factors associated with treatment (according to guideline) given to pregnant women with feverStatistical significanceDrug shop*P* = 0.04Private clinic*P* = 0.10Availability of malaria treatment guideline*P* = 0.03Presence of a functional laboratory*P* = 0.90Presence of a functional microscope*P* = 0.80Knowledge of people vulnerable to malaria*P* = 0.02Professional qualification of the provider*P* = 0.70Having attended a course on malaria management*P* = 0.80Having an RDT*P* = 0.04

Discussion {#Sec12}
==========

The present results show that treatment of pregnant women with fever according to national guidelines was poor in a substantial number of private health facilities, with less than 40 % of providers in private clinics, registered drug shops and pharmacies in rural Uganda knowing the correct first-line treatment for malaria during pregnancy. It is further shown that while majority of providers at private facilities correctly prescribed SP for IPTp, some drug shops also prescribed ACT and quinine for prevention of malaria in pregnancy. These results are compounded by low knowledge that pregnant women are at increased risk of malaria. These results have implications for the safety of pregnant women visiting private health facilities. Of immediate importance for the Ministry of Health is the need to design messages to create awareness that pregnant women are vulnerable to malaria and to distribute the most updated malaria treatment and prevention guideline to private health facilities.

It is shown that less than half of drug shops had rapid diagnostic tests (RDTs) (Table [3](#Tab3){ref-type="table"}). There is potential to scale up use of RDTs in these outlets based on recent findings that showed high adherence to RDT test results and improved appropriate treatment of malaria with ACT in drug shops \[[@CR17]\]. Nevertheless, in the private sector where RDTs exist, further operational research will be required to monitor adherence to RDT test results, treatment of non-malaria febrile illnesses and referral practices over time. It is shown that facilities which had RDTs were more likely to treat pregnant women with fever appropriately. This finding justifies the need to scale up this diagnostic tool.

Similar results have been documented in Nigeria where there was little knowledge about treatment and chemoprophylaxis for malaria in pregnancy especially in the private sector; and many providers could not recognize maternal and neonatal deaths as potential consequences of malaria in pregnancy \[[@CR20]\]. In Zambia, although not among pregnant women, approximately 30 % of patients who were found negative for malaria parasites were prescribed an anti-malarial drug contrary to the national guidelines \[[@CR21]\]. It was further shown that malaria case management was characterized by poor adherence to treatment guidelines, mainly due to inconsistent use of confirmatory tests (rapid diagnostic test or microscopy); prescribing anti-malarial drugs which were not recommended (e.g. sulfadoxine-pyrimethamine) and prescribing anti-malarial drugs to cases testing negative \[[@CR21]\].

Although the present results have highlighted deficiencies in treatment practices for fever in pregnancy and the need for improved policy guidance for providers in the private sector; similar concerns might also be raised in the public sector. A recent review showed that no country in sub-Saharan Africa provides appropriate guidance on management of uncomplicated and severe malaria during pregnancy \[[@CR22]\]. In all countries, inconsistencies between National Malaria Control programmes and Reproductive Health programmes on the timing or dose of IPTp-SP were documented, as was the mechanism for providing long-term insecticide-treated nets. Inconsistencies were also found in training documents from both programmes. It was concluded that out-dated and inconsistent guidelines had the potential to cause confusion and lead to incorrect practices among health workers who implement malaria in pregnancy programmes, contributing to low coverage of IPTp-SP and long-lasting insecticidal nets (LLINs) \[[@CR22], [@CR23]\].

Use and safety of drugs in pregnancy is a major concern. A study has recently shown that trimethoprim is a potential teratogen when used 3 months before pregnancy \[[@CR24]\]. It has also been found that Mefloquine as IPTp is not well tolerated, limiting its potential for IPTp and indicating the need to find alternatives with better tolerability to reduce malaria in this particularly vulnerable group \[[@CR25]\]. Accordingly, the World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria during the second and third trimesters of pregnancy, and quinine plus clindamycin during the first trimester \[[@CR26]\]. However, the national policies of many African countries currently recommend quinine throughout pregnancy. Although there are few reports of AL safety in the first trimester additional data are required to assess the potential to use AL in the first trimester \[[@CR26], [@CR27]\].

The immediate policy implications of these findings is to distribute the most updated malaria treatment and prevention guideline to private health facilities and to discuss with the Ministry of Health, district leaders, the national drug authority (NDA) and the professional councils that register private providers in Uganda to design continuing medical education (CME) and supervision modalities to ensure quality and safety of patients seeking care at these facilities. It is recommended that further studies to compare the effectiveness and cost of different supervision modalities for the private facilities and how best to link them to the public health system be conducted. Although interventions to improve quality of care in the private sector are recommended, there is caution that pregnant women may miss out on a wider ANC package like HIV testing and access to anti-retroviral therapy (ART) that may exist in the public sector. Thus a clear guideline is required on referral of pregnant women to ANC for other essential maternity care.

A limitation of this study is that treatment practices were never observed when pregnant women visited the facilities; neither was it possible to document what questions women asked when they visited the facilities. This however required an in-depth study that was beyond the scope of this study in terms of time and funds and exploration of these in further research is recommended. Nonetheless, the survey covered a large number of private health facilities and the treatment and prevention practices documented could be generalized to most parts of Uganda.

In conclusion, the study presents disturbing results that show poor treatment and prevention of malaria in pregnancy at private health facilities. Interventions to increase access to effective treatment and prevention of malaria in pregnancy in this sector are urgently needed.
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